Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Cisatracurium Besylate Patent Expiration

Cisatracurium Besylate is used for inducing muscle relaxation during surgical procedures. It was first introduced by Abbvie Inc in its drug Nimbex Preservative Free on Dec 15, 1995. Another drug containing Cisatracurium Besylate is Nimbex. 18 different companies have introduced drugs containing Cisatracurium Besylate.


Cisatracurium Besylate Patents

Given below is the list of patents protecting Cisatracurium Besylate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Nimbex US5453510 Neuromuscular blocking agents Sep 26, 2012

(Expired)

 Abbvie
Nimbex Preservative Free US5453510 Neuromuscular blocking agents Sep 26, 2012

(Expired)

 Abbvie



Cisatracurium Besylate's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Cisatracurium Besylate Generic API Manufacturers

Several generic applications have been filed for Cisatracurium Besylate. The first generic version for Cisatracurium Besylate was by Sandoz Inc and was approved on Feb 3, 2012. And the latest generic version is by Hainan Poly Pharm Co Ltd and was approved on Aug 27, 2024.

Given below is the list of companies who have filed for Cisatracurium Besylate generic, along with the locations of their manufacturing plants worldwide.